Moore Capital Management LP bought a new stake in Avanos Medical, Inc. (NYSE:AVNS - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 37,070 shares of the company's stock, valued at approximately $590,000. Moore Capital Management LP owned 0.08% of Avanos Medical at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in AVNS. T. Rowe Price Investment Management Inc. raised its stake in Avanos Medical by 27.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company's stock valued at $47,941,000 after acquiring an additional 644,267 shares during the period. Tributary Capital Management LLC increased its stake in shares of Avanos Medical by 38.1% in the fourth quarter. Tributary Capital Management LLC now owns 893,008 shares of the company's stock worth $14,217,000 after purchasing an additional 246,379 shares in the last quarter. Brown Advisory Inc. raised its position in shares of Avanos Medical by 12.0% in the fourth quarter. Brown Advisory Inc. now owns 1,905,094 shares of the company's stock valued at $30,329,000 after purchasing an additional 204,218 shares during the period. D. E. Shaw & Co. Inc. lifted its stake in shares of Avanos Medical by 43.1% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 494,627 shares of the company's stock valued at $7,874,000 after buying an additional 148,902 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Avanos Medical by 189.8% during the 4th quarter. JPMorgan Chase & Co. now owns 201,634 shares of the company's stock valued at $3,210,000 after buying an additional 132,063 shares in the last quarter. Hedge funds and other institutional investors own 95.17% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, StockNews.com raised shares of Avanos Medical from a "hold" rating to a "buy" rating in a report on Wednesday, March 19th.
Read Our Latest Research Report on AVNS
Avanos Medical Stock Performance
Shares of NYSE:AVNS traded down $0.41 during midday trading on Monday, reaching $12.70. 74,333 shares of the company traded hands, compared to its average volume of 355,111. The firm's fifty day moving average price is $13.19 and its two-hundred day moving average price is $15.70. The firm has a market capitalization of $587.30 million, a price-to-earnings ratio of 37.40 and a beta of 1.13. The company has a quick ratio of 1.46, a current ratio of 2.22 and a debt-to-equity ratio of 0.12. Avanos Medical, Inc. has a 12 month low of $11.84 and a 12 month high of $25.36.
Avanos Medical (NYSE:AVNS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.07. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%. The firm had revenue of $167.50 million for the quarter, compared to analysts' expectations of $161.75 million. During the same period in the prior year, the business posted $0.22 earnings per share. The company's revenue was up .8% on a year-over-year basis. On average, equities analysts expect that Avanos Medical, Inc. will post 1.32 earnings per share for the current year.
Insider Buying and Selling at Avanos Medical
In related news, SVP Kerr Holbrook sold 7,000 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $15.25, for a total value of $106,750.00. Following the sale, the senior vice president now owns 82,047 shares in the company, valued at approximately $1,251,216.75. This trade represents a 7.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 2.64% of the company's stock.
About Avanos Medical
(
Free Report)
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
See Also
Before you consider Avanos Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avanos Medical wasn't on the list.
While Avanos Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
